Related Experiment Video
Updated: Jan 20, 2026

EEG Mu Rhythm in Typical and Atypical Development
Published on: April 9, 2014
Aripiprazole: a new atypical antipsychotic drug
1Department of Pharmacy Practice, College of Pharmacy, University of Florida, Gainesville, FL, USA.
Objective:
To review the pharmacology, pharmacokinetics, clinical efficacy, and safety profile of aripiprazole for the treatment of schizophrenia.
Data Sources:
Information was selected from MEDLINE (1995-August 2002). Abstracts, scientific posters, and presentations were also used.
Study Selection/Data Extraction:
All published information regarding the pharmacokinetic, pharmacodynamic, and clinical characteristics of aripiprazole was considered. Studies providing a comprehensive description of aripiprazole were selected.
Data Synthesis:
Aripiprazole is a dopamine partial agonist and a serotonin-2A antagonist; it is dosed 10-30 mg/d, with no initial titration necessary. Short-term clinical trials demonstrated efficacy in acute exacerbations, and long-term studies showed that aripiprazole can maintain remission of schizophrenia. Most adverse events were mild. The incidence of extrapyramidal symptoms was low, with akathisia being the most common.
Conclusions:
Aripiprazole currently demonstrates comparable efficacy and safety for use in schizophrenia.
Related Concept Videos
FDA Approved Drugs: Changes to Approved Drugs
Bioequivalence of Drugs: Drugs with Multiple Indications
Pharmacokinetics: Drug–Drug Interactions
Antipsychotic Drugs: Typical and Atypical Agents
Psychosis and Antipsychotic Drugs: Overview
Antipsychotic Drugs: Therapeutic Uses and Side Effects
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...

